Objective To present a summary of the 2013 version of the European Association of Urology
(EAU) guidelines on the treatment of advanced, relapsing, and castration-resistant prostate …

Men with advanced prostate cancer are typically treated with hormonal therapy, which leads
to tumour shrinkage. However, tumours relapse and develop into the lethal form of the …

Objectives Our aim is to present a summary of the 2010 version of the European Association
of Urology (EAU) guidelines on the treatment of advanced, relapsing, and castration …

Study Type–Prognosis (cohort) Level of Evidence 2b What's known on the subject? and
What does the study add? Patients with biochemical recurrence after prostatectomy often …

Background. Substantial survival may be observed with oligometastatic prostate cancer.
Combining androgen deprivation (AD) and high-dose external beam radiotherapy (RT) to …

On April 29, 2010, the Food and Drug Administration (FDA) approved a new
immunotherapy, sipuleucel-T, for the treatment of patients with asymptomatic or minimally …

Background Clinical trials in men with biochemically recurrent prostate cancer (BRPC) have
been hampered by long survival times, making overall survival (OS) a difficult end point to …

Study Type–Therapy (RCT) Level of Evidence 1b What's known on the subject? and What
does the study add? Intermittent androgen deprivation therapy (ADT) involves cycling ADT …

Purpose The goal of this work was to evaluate the early efficacy of 68Ga-PSMA ligand
PET/CT imaging for radiotherapy of locally recurrent and/or oligometastatic prostate cancer …

We review and synthesize key findings and limitations of mathematical models for prostate
cancer, both from theoretical work and data-validated approaches, especially concerning …